Discussions

The future of oncology is no longer about treating "lung cancer" or "breast cancer"—it is about treating the specific genetic mutation driving a person’s tumor. Next Generation Sequencing is the engine behind this shift. By sequencing a patient's tumor DNA, doctors can identify the exact "drivers" of the cancer. This allows them to prescribe "targeted therapies"—drugs designed to attack only the cells with that specific mutation while sparing healthy ones. NGS has turned cancer treatment into a data-driven science, improving survival rates by matching the right drug to the right patient at the right time.

As these targeted treatments become more common, the role of Biosimilars grows in importance. Many of the most effective targeted therapies are biologics, which can be prohibitively expensive. Once the patents for these targeted biologics expire, biosimilar versions allow healthcare systems to provide the same high-standard genomic-based care at a fraction of the cost. By combining the diagnostic power of NGS to find the target and the affordability of biosimilars to provide the treatment, we are entering an era where personalized, high-tech medicine is no longer a luxury for the few, but a standard of care for everyone.